{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:56:20Z","timestamp":1792432580610,"version":"4.5.0"},"reference-count":205,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"abstract":"<jats:p>Approximately 70% of relapsing-remitting multiple sclerosis (RRMS) patients will develop secondary progressive multiple sclerosis (SPMS) within 10\u201315 years. This progression is characterized by a gradual decline in neurological functionality and increasing limitations of daily activities. Growing evidence suggests that both inflammation and neurodegeneration are associated with various pathological processes throughout the development of MS; therefore, to delay disease progression, it is critical to initiate disease-modifying therapy as soon as it is diagnosed. Currently, a diagnosis of SPMS requires a retrospective assessment of physical disability exacerbation, usually over the previous 6\u201312 months, which results in a delay of up to 3 years. Hence, there is a need to identify reliable and objective biomarkers for predicting and defining SPMS conversion. This review presents current knowledge of such biomarkers in the context of neurodegeneration associated with MS, and SPMS conversion.<\/jats:p>","DOI":"10.3389\/fnmol.2023.1210091","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T10:04:22Z","timestamp":1694513062000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review"],"prefix":"10.3389","volume":"16","author":[{"given":"Aleksandra","family":"Pogoda-Weso\u0142owska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dziedzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Maciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"St\u0229pie\u0144","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Dziaduch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Saluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33158-8","article-title":"Serum GFAP as a biomarker for disease severity in multiple sclerosis.","volume":"8","author":"Abdelhak","year":"2018","journal-title":"Sci. Rep."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00234","article-title":"Primary progressive multiple sclerosis: Putting together the puzzle.","volume":"8","author":"Abdelhak","year":"2017","journal-title":"Front. Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamaneurol.2019.2399","article-title":"Association of chronic active multiple sclerosis lesions with disability in vivo.","volume":"76","author":"Absinta","year":"2019","journal-title":"JAMA Neurol."},{"key":"B4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1212\/WNL.0000000000001587","article-title":"Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.","volume":"85","author":"Absinta","year":"2015","journal-title":"Neurology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5603\/PJNNS.a2020.0082","article-title":"Secondary progressive multiple sclerosis \u2014 from neuropathology to definition and effective treatment.","volume":"54","author":"Adamczyk-Sowa","year":"2020","journal-title":"Neurol. Neurochir. Polska"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/1352458512473362","article-title":"CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions.","volume":"19","author":"Alvarez","year":"2013","journal-title":"Mult. Scler. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M600933200","article-title":"Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease.","volume":"281","author":"Anderson","year":"2006","journal-title":"J. Biol. Chem."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003220","article-title":"Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis.","volume":"9","author":"Angelini","year":"2013","journal-title":"PLoS Pathog."},{"key":"B9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/jnc.13163","article-title":"Decreased levels of alpha-synuclein in cerebrospinal fluid of patients with clinically isolated syndrome and multiple sclerosis.","volume":"134","author":"Antonelou","year":"2015","journal-title":"J. Neurochem."},{"key":"B10","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","article-title":"Glial fibrillary acidic protein: A potential biomarker for progression in multiple sclerosis.","volume":"258","author":"Axelsson","year":"2011","journal-title":"J. Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jneuroim.2013.09.003","article-title":"The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.","volume":"264","author":"Axelsson","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67934-2","article-title":"Serum GFAP in multiple sclerosis: Correlation with disease type and MRI markers of disease severity.","volume":"10","author":"Ayrignac","year":"2020","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/biom12020222","article-title":"Neuroinflammation is associated with GFAP and sTREM2 levels in multiple sclerosis.","volume":"12","author":"Azzolini","year":"2022","journal-title":"Biomolecules"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1093\/brain\/awr278","article-title":"Tracking iron in multiple sclerosis: A combined imaging and histopathological study at 7 Tesla.","author":"Bagnato","year":"2011","journal-title":"Brain"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.01026","article-title":"Cerebrospinal fluid and blood cytokines as biomarkers for multiple sclerosis: A systematic review and meta-analysis of 226 studies with 13,526 multiple sclerosis patients.","volume":"13","author":"Bai","year":"2019","journal-title":"Front. Neurosci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","article-title":"Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.","volume":"141","author":"Barro","year":"2018","journal-title":"Brain"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8626","DOI":"10.1523\/jneurosci.3817-14.2015","article-title":"Transfer of myelin-reactive th17 cells impairs endogenous remyelination in the central nervous system of cuprizone-fed mice.","volume":"35","author":"Baxi","year":"2015","journal-title":"J. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ng.2770","article-title":"Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis.","volume":"45","author":"Beecham","year":"2013","journal-title":"Nat. Genet."},{"key":"B19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.pharmthera.2004","article-title":"The role of alpha-synuclein in neurodegenerative diseases.","volume":"105","author":"Bennett","year":"2005","journal-title":"Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3174\/ajnr.A6011","article-title":"Leptomeningeal contrast enhancement is related to focal cortical thinning in relapsing-remitting multiple sclerosis: A cross-sectional MRI study.","volume":"40","author":"Bergsland","year":"2019","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1177\/1352458515616204","article-title":"Localized atrophy of the thalamus and slowed cognitive processing speed in MS patients.","volume":"22","author":"Bergsland","year":"2016","journal-title":"Mult. Scler."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1177\/1352458518782005","article-title":"Neurofilaments and 10-year follow-up in multiple sclerosis.","volume":"24","author":"Bhan","year":"2018","journal-title":"Mult. Scler."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577432","article-title":"Low serum A -SYNUCLEIN and oligomer A -SYNUCLEIN levels in multiple sclerosis patients.","volume":"350","author":"Bilge","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1080\/03007995.2016.1222516","article-title":"Evaluation of the expanded disability status scale and the multiple sclerosis functional composite as clinical endpoints in multiple sclerosis clinical trials: Quantitative meta-analyses.","volume":"32","author":"Bin Sawad","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"B25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B","article-title":"Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients.","volume":"48","author":"Bjartmar","year":"2000","journal-title":"Ann. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"7380","DOI":"10.1007\/s12035-019-1615-1","article-title":"Panoramic visualization of circulating MicroRNAs across neurodegenerative diseases in humans.","volume":"56","author":"Brennan","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.molcel.2016.09.004","article-title":"Pairing beyond the seed supports MicroRNA targeting specificity.","volume":"64","author":"Broughton","year":"2016","journal-title":"Mol. Cell"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-022-01480-y","article-title":"SNCA genetic lowering reveals differential cognitive function of alpha-synuclein dependent on sex.","volume":"10","author":"Brown","year":"2022","journal-title":"Acta Neuropathol. Commun."},{"key":"B29","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3233\/jpd-150642","article-title":"The synaptic function of \u03b1-synuclein.","volume":"5","author":"Burr\u00e9","year":"2015","journal-title":"J. Parkinsons Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/1352458516638941","article-title":"The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis.","volume":"23","author":"Cadavid","year":"2017","journal-title":"Mult. Scler."},{"key":"B31","first-page":"321","article-title":"[Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis].","volume":"51","author":"Cadavid","year":"2010","journal-title":"Rev. Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/1352458520958589","article-title":"In vivo imaging of chronic active lesions in multiple sclerosis.","volume":"28","author":"Calvi","year":"2022","journal-title":"Mult. Scler."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028985","article-title":"Neurodegeneration in progressive multiple sclerosis.","volume":"8","author":"Campbell","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/jon.12553","article-title":"Spinal cord atrophy in multiple sclerosis: A systematic review and meta-analysis.","volume":"28","author":"Casserly","year":"2018","journal-title":"J. Neuroimaging"},{"key":"B35","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.1073\/pnas.100076197","article-title":"Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule.","volume":"97","author":"Charles","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3174\/ajnr.A4729","article-title":"Iron and non-iron-related characteristics of multiple sclerosis and neuromyelitis optica lesions at 7T MRI.","volume":"37","author":"Chawla","year":"2016","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn1298","article-title":"Regulation of \u03b1-synuclein homeostasis and inflammasome activation by microglial autophagy.","volume":"8","author":"Choi","year":"2022","journal-title":"Sci. Adv."},{"key":"B38","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/s1474-4422(14)70101-2","article-title":"Pathogenesis of multiple sclerosis: Insights from molecular and metabolic imaging.","volume":"13","author":"Ciccarelli","year":"2014","journal-title":"Lancet Neurol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41577-023-00837-1","article-title":"The biology of TREM receptors.","volume":"23","author":"Colonna","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001082","article-title":"CSF chitinase 3-like 2 is associated with long-term disability progression in patients with progressive multiple sclerosis.","volume":"8","author":"Comabella","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-017-0424-x","article-title":"A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis.","volume":"5","author":"Cooper-Knock","year":"2017","journal-title":"Acta Neuropathol. Commun."},{"key":"B42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/ane.12431","article-title":"Multiple sclerosis and environmental factors: The role of vitamin D, parasites, and Epstein-Barr virus infection.","volume":"132","author":"Correale","year":"2015","journal-title":"Acta Neurol. Scand."},{"key":"B43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00401-016-1636-z","article-title":"Slow expansion of multiple sclerosis iron rim lesions: Pathology and 7 T magnetic resonance imaging.","volume":"133","author":"Dal-Bianco","year":"2017","journal-title":"Acta Neuropathol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/brain\/awaa436","article-title":"Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI.","volume":"144","author":"Dal-Bianco","year":"2021","journal-title":"Brain"},{"key":"B45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40263-014-0140-z","article-title":"Clinical relevance of brain volume measures in multiple sclerosis.","volume":"28","author":"De Stefano","year":"2014","journal-title":"CNS Drugs"},{"key":"B46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/jnnp-2014-309903","article-title":"Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis.","volume":"87","author":"De Stefano","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","article-title":"Immunopathology of multiple sclerosis.","volume":"15","author":"Dendrou","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"B48","first-page":"2275","article-title":"Neurodegeneration and cognition in Parkinson\u2019s disease: A review.","volume":"19","author":"Ding","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/2055217320981396","article-title":"Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis.","volume":"6","author":"DiSano","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"B50","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","article-title":"Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis.","volume":"81","author":"Disanto","year":"2017","journal-title":"Ann. Neurol."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02443-9","article-title":"CSF sTREM2 in neurological diseases: A two-sample Mendelian randomization study.","volume":"19","author":"Dong","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"B52","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1212\/01.wnl.0000150542.16969.cc","article-title":"Dehydration confounds the assessment of brain atrophy.","volume":"64","author":"Duning","year":"2005","journal-title":"Neurology"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14301-3","article-title":"Exosomal microRNA signatures in multiple sclerosis reflect disease status.","volume":"7","author":"Ebrahimkhani","year":"2017","journal-title":"Sci. Rep."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1348","DOI":"10.1212\/wnl.0000000000008198","article-title":"Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis.","volume":"93","author":"Eijlers","year":"2019","journal-title":"Neurology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/brain\/awy202","article-title":"Predicting cognitive decline in multiple sclerosis: A 5-year follow-up study.","volume":"141","author":"Eijlers","year":"2018","journal-title":"Brain"},{"key":"B56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1083\/jcb.146.1.181","article-title":"Age-related atrophy of motor axons in mice deficient in the mid-sized neurofilament subunit.","volume":"146","author":"Elder","year":"1999","journal-title":"J. Cell Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1212\/01.wnl.0000161871.83614.bb","article-title":"Risk factors for progression of brain atrophy in aging: Six-year follow-up of normal subjects.","volume":"64","author":"Enzinger","year":"2005","journal-title":"Neurology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/ana.25145","article-title":"Deep gray matter volume loss drives disability worsening in multiple sclerosis.","volume":"83","author":"Eshaghi","year":"2018","journal-title":"Ann. Neurol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-016-0694-4","article-title":"\u03b1-Synuclein deficiency promotes neuroinflammation by increasing Th1 cell-mediated immune responses.","volume":"13","author":"Ettle","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"B60","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","article-title":"Progressive multiple sclerosis: From pathophysiology to therapeutic strategies.","volume":"18","author":"Faissner","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B61","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1093\/brain\/120.3.393","article-title":"Axonal damage in acute multiple sclerosis lesions.","author":"Ferguson","year":"1997","journal-title":"Brain"},{"key":"B62","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jneuroim.2015.04.011","article-title":"Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis.","volume":"283","author":"Ferraro","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/ane.13152","article-title":"Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients.","volume":"141","author":"Ferraro","year":"2020","journal-title":"Acta Neurol. Scand."},{"key":"B64","doi-asserted-by":"crossref","first-page":"23","DOI":"10.14712\/fb2009055010023","article-title":"Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases.","volume":"55","author":"Fialov\u00e1","year":"2009","journal-title":"Folia Biol. (Praha)"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/brain\/awt1","article-title":"Disease-specific molecular events in cortical multiple sclerosis lesions.","author":"Fischer","year":"2013","journal-title":"Brain"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1093\/brain\/awaa117","article-title":"Tissue-resident memory T cells invade the brain parenchyma in multiple sclerosis white matter lesions.","volume":"143","author":"Fransen","year":"2020","journal-title":"Brain"},{"key":"B67","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2014.37","article-title":"Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis.","volume":"10","author":"Friese","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.23880","article-title":"Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.","volume":"73","author":"Gandhi","year":"2013","journal-title":"Ann. Neurol."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2091-2","article-title":"Mitochondrial damage by \u03b1-synuclein causes cell death in human dopaminergic neurons.","volume":"10","author":"Ganjam","year":"2019","journal-title":"Cell Death Dis."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0071634","article-title":"Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson\u2019s disease.","volume":"8","author":"Gardai","year":"2013","journal-title":"PLoS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073461","article-title":"Microglia: The missing link to decipher and therapeutically control MS progression?","volume":"22","author":"Geladaris","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1126\/science.290.5493.985","article-title":"Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions.","volume":"290","author":"Giasson","year":"2000","journal-title":"Science"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01008","article-title":"Combined cerebrospinal fluid neurofilament light chain protein and chitinase-3 Like-1 levels in defining disease course and prognosis in multiple sclerosis.","volume":"10","author":"Gil-Perotin","year":"2019","journal-title":"Front. Neurol."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070019","article-title":"Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression.","volume":"8","author":"Gnanapavan","year":"","journal-title":"PLoS One"},{"key":"B75","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/jnc.12236","article-title":"Progression in multiple sclerosis is associated with low endogenous NCAM.","volume":"125","author":"Gnanapavan","year":"","journal-title":"J. Neurochem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181a8260a","article-title":"Remyelination capacity of the MS brain decreases with disease chronicity.","volume":"72","author":"Goldschmidt","year":"2009","journal-title":"Neurology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.4103\/1673-5374.239432","article-title":"Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: Perspectives and approaches.","volume":"13","author":"Grand\u2019Maison","year":"2018","journal-title":"Neural Regen. Res."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1136\/jnnp-2013-306789","article-title":"Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients.","volume":"85","author":"Gresle","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B79","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.pharmthera.2018.09.003","article-title":"TSPO in diverse CNS pathologies and psychiatric disease: A critical review and a way forward.","volume":"194","author":"Guilarte","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1212\/WNL.0b013e3182759621","article-title":"Regulated microRNAs in the CSF of patients with multiple sclerosis: A case-control study.","volume":"79","author":"Haghikia","year":"2012","journal-title":"Neurology"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1249-7","article-title":"Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis.","volume":"15","author":"H\u00e5kansson","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00459","article-title":"Thalamic atrophy without whole brain atrophy is associated with absence of 2-year NEDA in multiple sclerosis.","volume":"10","author":"H\u00e4nninen","year":"2019","journal-title":"Front. Neurol."},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00606","article-title":"Thalamic atrophy predicts 5-year disability progression in multiple sclerosis.","volume":"11","author":"H\u00e4nninen","year":"2020","journal-title":"Front. Neurol."},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01046","article-title":"A pilot cross-sectional study to investigate the biomarker potential of phosphorylated neurofilament-H and immune mediators of disability in patients with 5 year relapsing-remitting multiple sclerosis.","volume":"10","author":"Herrera","year":"2019","journal-title":"Front. Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1177\/1352458514561906","article-title":"Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis","volume":"21","author":"Hinsinger","year":"2015","journal-title":"Mult Scler"},{"key":"B86","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1352458518819380","article-title":"Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.","volume":"26","author":"H\u00f6gel","year":"2020","journal-title":"Mult. Scler."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.875","article-title":"Progressive multiple sclerosis, cognitive function, and quality of life.","volume":"8","author":"H\u00f8jsgaard Chow","year":"2018","journal-title":"Brain Behav."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis.","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"key":"B89","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5507\/bp.2023.002","article-title":"Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.","volume":"167","author":"Hradilek","year":"2023","journal-title":"Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech. Repub."},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.102939","article-title":"Leptomeningeal enhancement in multiple sclerosis and other neurological diseases: A systematic review and Meta-Analysis.","volume":"33","author":"Ineichen","year":"2022","journal-title":"Neuroimage Clin."},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1177\/20552173211019772","article-title":"Correlations between macrophage\/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis.","volume":"7","author":"Ioannides","year":"2021","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9899.1000460","article-title":"Regulated production of CXCL13 within the central nervous system.","volume":"7","author":"Irani","year":"2016","journal-title":"J. Clin. Cell. Immunol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jns.2017.06.048","article-title":"CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.","volume":"380","author":"Iwanowski","year":"2017","journal-title":"J. Neurol. Sci."},{"key":"B94","doi-asserted-by":"publisher","first-page":"613","DOI":"10.14348\/molcells.2017.0096","article-title":"Molecular and cellular basis of neurodegeneration in Alzheimer\u2019s disease.","volume":"40","author":"Jeong","year":"2017","journal-title":"Mol. Cells"},{"key":"B95","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/bf01694535","article-title":"Neural cell adhesion molecule (NCAM) as a quantitative marker in synaptic remodeling.","volume":"20","author":"J\u00f8rgensen","year":"1995","journal-title":"Neurochem. Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1177\/1352458518803785","article-title":"Recommendations for cognitive screening and management in multiple sclerosis care.","volume":"24","author":"Kalb","year":"2018","journal-title":"Mult. Scler."},{"key":"B97","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1352458510389102","article-title":"Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course.","volume":"17","author":"Khademi","year":"2011","journal-title":"Mult. Scler."},{"key":"B98","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/13524585124580","article-title":"CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome.","volume":"19","author":"Khalil","year":"2013","journal-title":"Mult. Scler."},{"key":"B99","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","article-title":"Neurofilaments as biomarkers in neurological disorders.","volume":"14","author":"Khalil","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/ene.14732","article-title":"Is the Symbol Digit Modalities Test a useful outcome in secondary progressive multiple sclerosis?","volume":"28","author":"Koch","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ana.24408","article-title":"Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis.","volume":"78","author":"Komori","year":"2015","journal-title":"Ann. Neurol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1002\/jcp.299","article-title":"MiRNA-145-5p prevents differentiation of oligodendrocyte progenitor cells by regulating expression of myelin gene regulatory factor.","volume":"236","author":"Kornfeld","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000623","article-title":"Elevated levels of miR-181c and miR-633 in the CSF of patients with MS: A validation study.","volume":"6","author":"Kramer","year":"2019","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B104","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/brain\/awh680","article-title":"Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.","author":"Krumbholz","year":"2006","journal-title":"Brain"},{"key":"B105","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1007\/s12031-020-01498-8","article-title":"alpha-Synuclein: A modulator during inflammatory CNS demyelination.","volume":"70","author":"Kuhbandner","year":"2020","journal-title":"J. Mol. Neurosci."},{"key":"B106","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1111\/ane.12151","article-title":"Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.","volume":"128","author":"Kuhle","year":"2013","journal-title":"Acta Neurol. Scand."},{"key":"B107","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1212\/wnl.0000000000003653","article-title":"Serum neurofilament is associated with progression of brain atrophy and disability in early MS.","volume":"88","author":"Kuhle","year":"2017","journal-title":"Neurology"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1093\/brain\/awh641","article-title":"Cortical demyelination and diffuse white matter injury in multiple sclerosis.","author":"Kutzelnigg","year":"2005","journal-title":"Brain"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: The roles of microglia and astrocytes.","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl. Neurodegener."},{"key":"B110","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrn3406","article-title":"The many faces of \u03b1-synuclein: From structure and toxicity to therapeutic target.","volume":"14","author":"Lashuel","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2013.05.0","article-title":"Pathology and disease mechanisms in different stages of multiple sclerosis.","volume":"333","author":"Lassmann","year":"2013","journal-title":"J. Neurol. Sci."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1601-6","article-title":"Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases.","volume":"16","author":"Lepennetier","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"B113","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1177\/1352458517699874","article-title":"Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.","volume":"24","author":"Leurs","year":"2018","journal-title":"Mult. Scler."},{"key":"B114","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1177\/1352458512463482","article-title":"Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13.","volume":"19","author":"Lind\u00e9n","year":"2013","journal-title":"Mult. Scler."},{"key":"B115","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2020.08.012","article-title":"Astrocyte Crosstalk in CNS Inflammation.","volume":"108","author":"Linnerbauer","year":"2020","journal-title":"Neuron"},{"key":"B116","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s12640-016-9639-z","article-title":"The validation study of neurofilament heavy chain and 8-hydroxy-2\u2019-deoxyguanosine as plasma biomarkers of clinical\/paraclinical activity in first and relapsing-remitting demyelination acute attacks.","volume":"30","author":"Ljubisavljevic","year":"2016","journal-title":"Neurotox. Res."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-015-0296-2","article-title":"A one-year follow-up study of the Symbol digit modalities test (SDMT) and the paced auditory serial addition test (PASAT) in relapsing-remitting multiple sclerosis: An appraisal of comparative longitudinal sensitivity.","volume":"15","author":"L\u00f3pez-G\u00f3ngora","year":"2015","journal-title":"BMC Neurol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis.","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"key":"B119","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.mito.2018.07.008","article-title":"Cell-free mitochondrial DNA in progressive multiple sclerosis.","volume":"46","author":"Lowes","year":"2019","journal-title":"Mitochondrion"},{"key":"B120","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/NEN.0b013e318196e905","article-title":"Association of alpha-synuclein immunoreactivity with inflammatory activity in multiple sclerosis lesions.","volume":"68","author":"Lu","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: The 2013 revisions.","volume":"83","author":"Lublin","year":"2014","journal-title":"Neurology"},{"key":"B122","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00401-018-1818-y","article-title":"Progressive multiple sclerosis patients show substantial lesion activity that correlates with clinical disease severity and sex: A retrospective autopsy cohort analysis.","volume":"135","author":"Luchetti","year":"2018","journal-title":"Acta Neuropathol."},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04422-2","article-title":"\u03b1-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease.","volume":"9","author":"Ludtmann","year":"2018","journal-title":"Nat. Commun."},{"key":"B124","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1172\/jci130351","article-title":"Oxidative stress and \u03b1-synuclein conspire in vulnerable neurons to promote Parkinson\u2019s disease progression.","volume":"129","author":"Luk","year":"2019","journal-title":"J. Clin. Invest."},{"key":"B125","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1136\/jnnp-2014-308021","article-title":"Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis.","volume":"86","author":"Lukas","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"B126","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s1474-4422(14)70256-x","article-title":"Pathological mechanisms in progressive multiple sclerosis.","volume":"14","author":"Mahad","year":"2015","journal-title":"Lancet Neurol."},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8652463","article-title":"Leptomeningeal contrast enhancement is associated with disability progression and grey matter atrophy in multiple sclerosis.","volume":"2017","author":"Makshakov","year":"2017","journal-title":"Neurol. Res. Int."},{"key":"B128","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.msard.2019.02.021","article-title":"Cognitive speed and white matter integrity in secondary progressive multiple sclerosis.","volume":"30","author":"Manca","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0504-2","article-title":"MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.","volume":"13","author":"Mancuso","year":"2015","journal-title":"J. Transl. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"606","DOI":"10.4103\/1673-5374.266905","article-title":"MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression.","volume":"15","author":"Martinez","year":"2020","journal-title":"Neural Regen. Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis.","volume":"50","author":"McDonald","year":"2001","journal-title":"Ann. Neurol."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057573","article-title":"Iron is a sensitive biomarker for inflammation in multiple sclerosis lesions.","volume":"8","author":"Mehta","year":"2013","journal-title":"PLoS One"},{"key":"B133","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3109\/09540261003589372","article-title":"Assessment and rehabilitation of cognitive impairment in multiple sclerosis.","volume":"22","author":"Messinis","year":"2010","journal-title":"Int. Rev. Psychiatry"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419840593","article-title":"Advances in spinal cord imaging in multiple sclerosis.","volume":"12","author":"Moccia","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200069","article-title":"miRNA signature in CSF from patients with primary progressive multiple sclerosis.","volume":"10","author":"Mu\u00f1oz-San Mart\u00edn","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B136","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neuroimage.2015.05.077","article-title":"Diurnal fluctuations in brain volume: Statistical analyses of MRI from large populations.","volume":"118","author":"Nakamura","year":"2015","journal-title":"Neuroimage"},{"key":"B137","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neuron.2009.12.023","article-title":"Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.","volume":"65","author":"Nemani","year":"2010","journal-title":"Neuron"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577465","article-title":"The serum alpha-synuclein levels in patients with multiple sclerosis need more evidence.","volume":"352","author":"Niu","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102463","article-title":"NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS.","volume":"46","author":"Novakova","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B140","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/1874205x01812010019","article-title":"Cognitive and language deficits in multiple sclerosis: Comparison of relapsing remitting and secondary progressive subtypes.","volume":"12","author":"Ntoskou","year":"2018","journal-title":"Open Neurol. J."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1177\/1352458515624558","article-title":"Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.","volume":"22","author":"\u00d6hrfelt","year":"2016","journal-title":"Mult. Scler."},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045409","article-title":"Comparison of disease activity in SPMS and PPMS in the context of multicenter clinical trials.","volume":"7","author":"Orbach","year":"2012","journal-title":"PLoS One"},{"key":"B143","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092099","article-title":"The brave new world of early treatment of multiple sclerosis: Using the molecular biomarkers CXCL13 and neurofilament light to optimize immunotherapy.","volume":"10","author":"Pachner","year":"2022","journal-title":"Biomedicines"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.850998","article-title":"Role of the CXCL13\/CXCR5 axis in autoimmune diseases.","volume":"13","author":"Pan","year":"2022","journal-title":"Front. Immunol."},{"key":"B145","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jocn.2017.05.032","article-title":"Corpus callosum atrophy as a marker of clinically meaningful cognitive decline in secondary progressive multiple sclerosis. Impact on employment status.","volume":"43","author":"Papathanasiou","year":"2017","journal-title":"J. Clin. Neurosci."},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0349-x","article-title":"Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway.","volume":"15","author":"Park","year":"2020","journal-title":"Mol. Neurodegener."},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2019.e02590","article-title":"Alpha synuclein in hematopoiesis and immunity.","volume":"5","author":"Pei","year":"2019","journal-title":"Heliyon"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1177\/1352458516645206","article-title":"Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.","volume":"22","author":"Petzold","year":"2016","journal-title":"Mult. Scler. J."},{"key":"B149","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awn217","article-title":"Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation.","author":"Piccio","year":"2008","journal-title":"Brain"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111887","article-title":"Circulating miRNAs as potential biomarkers distinguishing relapsing-remitting from secondary progressive multiple sclerosis. A review.","volume":"22","author":"Pietrasik","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B151","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/ana.23955","article-title":"Low cerebrospinal fluid concentration of mitochondrial DNA in preclinical Alzheimer disease.","volume":"74","author":"Podlesniy","year":"2013","journal-title":"Ann. Neurol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ana.1255","article-title":"Immunopathology of secondary-progressive multiple sclerosis.","volume":"50","author":"Prineas","year":"2001","journal-title":"Ann. Neurol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/ana.24515","article-title":"Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson\u2019s disease.","volume":"78","author":"Pyle","year":"2015","journal-title":"Ann. Neurol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/1352458511398887","article-title":"Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid.","volume":"17","author":"Ragheb","year":"2011","journal-title":"Mult. Scler. J."},{"key":"B156","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/jad-181179","article-title":"Choroid plexus acts as gatekeeper for TREM2, abnormal accumulation of ApoE, and fibrillary tau in Alzheimer\u2019s disease and in down syndrome dementia.","volume":"69","author":"Raha-Chowdhury","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"B157","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10571-022-01200-z","article-title":"Roles of the miR-155 in neuroinflammation and neurological disorders: A potent biological and therapeutic target.","volume":"43","author":"Rastegar-Moghaddam","year":"2023","journal-title":"Cell. Mol. Neurobiol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neurobiolaging.2018","article-title":"CSF soluble TREM2 as a measure of immune response along the Alzheimer\u2019s disease continuum.","volume":"74","author":"Rauchmann","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285022","article-title":"Predictive value of \u03b1-synuclein expression in peripheral blood of multiple sclerosis patients: A two-dimensional assessment of a selected biomarker.","volume":"18","author":"Razia","year":"2023","journal-title":"PLoS One"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000491","article-title":"Identification of MS-specific serum miRNAs in an international multicenter study.","volume":"5","author":"Regev","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000267","article-title":"Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis.","volume":"3","author":"Regev","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"B162","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.82.10_supplement.S44.001","article-title":"Leptomeningeal contrast enhancement in multiple sclerosis: A possible marker of inflammation in the subarachnoid space.","author":"Reich","year":"2014","journal-title":"Neurology"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104177","article-title":"Serum neurofilament levels in patients with multiple sclerosis: A comparison of SIMOA and high sensitivity ELISA assays and contributing factors to ELISA levels.","volume":"67","author":"Revendova","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057820","article-title":"Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression.","volume":"8","author":"Romme Christensen","year":"2013","journal-title":"PLoS One"},{"key":"B165","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1600-0404.2007.00972.x","article-title":"The reliability of the MSFC and its components.","volume":"117","author":"Rosti-Otaj\u00e4rvi","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"B166","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrneurol.2015.106","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process.","volume":"11","author":"Rovira","year":"2015","journal-title":"Nat. Rev. Neurol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1177\/1756285613484079","article-title":"Magnetic resonance monitoring of lesion evolution in multiple sclerosis.","volume":"6","author":"Rovira","year":"2013","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"B168","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/1352458509359725","article-title":"Neurofilament light as a prognostic marker in multiple sclerosis.","volume":"16","author":"Salzer","year":"2010","journal-title":"Mult. Scler."},{"key":"B169","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.nic.2017.01.002","article-title":"Brain atrophy in multiple sclerosis: Clinical relevance and technical aspects.","volume":"27","author":"Sastre-Garriga","year":"2017","journal-title":"Neuroimaging Clin. N. Am."},{"key":"B170","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41582-020-0314-x","article-title":"MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.","volume":"16","author":"Sastre-Garriga","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1523\/jneurosci.2456-15.2016","article-title":"Neurodegeneration triggers peripheral immune cell recruitment into the forebrain.","volume":"36","author":"Scheld","year":"2016","journal-title":"J. Neurosci."},{"key":"B172","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/ana.24241","article-title":"Spinal cord gray matter atrophy correlates with multiple sclerosis disability.","volume":"76","author":"Schlaeger","year":"2014","journal-title":"Ann. Neurol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","article-title":"Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.","volume":"14","author":"Serafini","year":"2004","journal-title":"Brain Pathol."},{"key":"B174","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.imbio.2015","article-title":"A critical role for alpha-synuclein in development and function of T lymphocytes.","volume":"221","author":"Shameli","year":"2016","journal-title":"Immunobiology"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02802","article-title":"Autoimmune glial fibrillary acidic protein astrocytopathy: A review of the literature.","volume":"9","author":"Shan","year":"2018","journal-title":"Front. Immunol."},{"key":"B176","first-page":"1","article-title":"Serum phosphorylated neurofilament heavy chain level in relapsing remitting multiple sclerosis in correlation to disease activity and disability.","volume":"26","author":"Shehab","year":"2019","journal-title":"Egypt. J. Immunol."},{"key":"B177","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00401-013-1082-0","article-title":"Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons.","volume":"125","author":"Singh","year":"2013","journal-title":"Acta Neuropathol."},{"key":"B178","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1084\/jem.20171529","article-title":"Humanized TREM2 mice reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism.","volume":"215","author":"Song","year":"2018","journal-title":"J. Exp. Med."},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101426","article-title":"Correlation between EDSS scores and cervical spinal cord atrophy at 3T MRI in multiple sclerosis: A systematic review and meta-analysis.","volume":"37","author":"Song","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B180","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/brain\/awv337","article-title":"Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant.","author":"Steenwijk","year":"2016","journal-title":"Brain"},{"key":"B181","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1177\/1352458518808204","article-title":"Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.","volume":"25","author":"Strober","year":"2019","journal-title":"Mult. Scler."},{"key":"B182","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/brain\/awaa275","article-title":"Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.","volume":"143","author":"Sucksdorff","year":"2020","journal-title":"Brain"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/s0140-6736(18)30481-1","article-title":"Multiple sclerosis.","volume":"391","author":"Thompson","year":"","journal-title":"Lancet"},{"key":"B184","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/s1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.","volume":"17","author":"Thompson","year":"","journal-title":"Lancet Neurol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"44405","DOI":"10.1074\/jbc.M308041200","article-title":"Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.","volume":"278","author":"Tofaris","year":"2003","journal-title":"J. Biol. Chem."},{"key":"B186","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1056\/nejm199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis.","volume":"338","author":"Trapp","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"B187","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mito.2016.12.003","article-title":"Increased levels of cell-free mitochondrial DNA in the cerebrospinal fluid of patients with multiple sclerosis.","volume":"34","author":"Varhaug","year":"2017","journal-title":"Mitochondrion"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102840","article-title":"Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis.","volume":"50","author":"Verberk","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"B189","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J."},{"key":"B190","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1471-4159.2012.07749.x","article-title":"Cerebrospinal fluid \u03b1-synuclein levels are elevated in multiple sclerosis and neuromyelitis optica patients during replase.","volume":"122","author":"Wang","year":"2012","journal-title":"J. Neurochem."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1002\/acn3.50862","article-title":"Environmental and genetic risk factors for MS: An integrated review.","volume":"6","author":"Waubant","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"B192","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1471-4159.2011.07536.x","article-title":"Pathogenic implications of iron accumulation in multiple sclerosis.","volume":"120","author":"Williams","year":"2012","journal-title":"J. Neurochem."},{"key":"B193","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1007\/s00415-020-09917-x","article-title":"Neurofilaments in progressive multiple sclerosis: A systematic review.","volume":"268","author":"Williams","year":"2021","journal-title":"J. Neurol."},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-018-0405-8","article-title":"Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup.","volume":"10","author":"Woollacott","year":"2018","journal-title":"Alzheimers Res. Ther."},{"key":"B195","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s12035-013-8584-6","article-title":"Wnt signaling in remyelination in multiple sclerosis: Friend or foe?","volume":"49","author":"Xie","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"11165","DOI":"10.1523\/jneurosci.2559-04.2004","article-title":"Role of alpha-synuclein in presynaptic dopamine recruitment.","volume":"24","author":"Yavich","year":"2004","journal-title":"J. Neurosci."},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a018309","article-title":"Neurofilaments and neurofilament proteins in health and disease.","volume":"9","author":"Yuan","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00328","article-title":"The emerging roles and therapeutic potential of soluble TREM2 in Alzheimer\u2019s disease.","volume":"11","author":"Zhong","year":"2019","journal-title":"Front. Aging Neurosci."},{"key":"B199","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3389\/fneur.2020.00132","article-title":"A meta-analytic review of the value of miRNA for multiple sclerosis diagnosis.","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Neurol."},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0639-7","article-title":"Multiple sclerosis: Clinical profiling and data collection as prerequisite for personalized medicine approach.","volume":"16","author":"Ziemssen","year":"2016","journal-title":"BMC Neurol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/14737175.2016.1181543","article-title":"Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine.","volume":"16","author":"Zivadinov","year":"","journal-title":"Expert Rev. Neurother."},{"key":"B202","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3174\/ajnr.A4681","article-title":"Autoimmune comorbidities are associated with brain injury in multiple sclerosis.","volume":"37","author":"Zivadinov","year":"","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1177\/1352458516678083","article-title":"Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study.","volume":"23","author":"Zivadinov","year":"2017","journal-title":"Mult. Scler."},{"key":"B204","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/01.wnl.00003168","article-title":"Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.","volume":"71","author":"Zivadinov","year":"2008","journal-title":"Neurology"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-020-00406-3","article-title":"Neurofilaments in motor neuron disorders: Towards promising diagnostic and prognostic biomarkers.","volume":"15","author":"Zucchi","year":"2020","journal-title":"Mol. Neurodegener."}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2023.1210091\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,27]],"date-time":"2024-10-27T23:21:17Z","timestamp":1730071277000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2023.1210091\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":205,"alternative-id":["10.3389\/fnmol.2023.1210091"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2023.1210091","relation":{},"ISSN":["1662-5099"],"issn-type":[{"value":"1662-5099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]},"article-number":"1210091"}}